Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Public ClinicalTrials.gov record NCT05400122. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients With Locally Advanced/Metastatic Colorectal Cancer, Gastric/Esophageal Cancer, and Relapsed/Refractory Hematologic Malignancies
Study identification
- NCT ID
- NCT05400122
- Recruitment status
- Suspended
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- David Wald
- Other
- Enrollment
- 12 participants
Conditions and interventions
Conditions
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Myeloid Leukemia
- Colorectal Cancer
- Esophageal Cancer
- Esophagus Cancer
- Gastric Cancer
- Gastric Cancer, Metastatic
- Hematologic Malignancy
- Hodgkin Lymphoma
- Metastatic Esophageal Cancer
- Myelodysplastic Syndromes
- Myeloproliferative Syndrome
- Non Hodgkin Lymphoma
- Plasma Cell Myeloma
- Rectum Cancer
- Unresectable Esophageal Cancer
Interventions
- Cyclophosphamide Drug
- Fludarabine Phosphate Drug
- IL-2 Drug
- Natural Killer Cells Drug
- Vactosertib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 8, 2022
- Primary completion
- Dec 30, 2025
- Completion
- May 31, 2026
- Last update posted
- Nov 11, 2025
2022 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center | Cleveland | Ohio | 44106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05400122, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 11, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05400122 live on ClinicalTrials.gov.